logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5447.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5447.produseast1
Costs, cost-effectiveness, and financing of tuberculosis treatment | Collections | MSF Science Portal
Costs, cost-effectiveness, and financing of tuberculosis treatment

Costs, cost-effectiveness, and financing of tuberculosis treatment

Tuberculosis (TB) is the world's deadliest infectious disease, and the leading killer of people with HIV. TB is curable, but it can be difficult to diagnose and tough to treat, especially for increasingly prevalent drug-resistant TB. In 2023, 22,700 people started TB treatment in MSF programs. Understanding the costs and cost-effectiveness associated with TB treatment and innovations, ranging from TB diagnostics and medications to TB care models, can help to plan resource needs and allocate resources effectively. Analyzing financing mechanisms can support developing sustainable funding models for TB control.

This collection spotlights articles by MSF and collaborators to analyze and document the costs of care, particularly diagnostics and medications.

Collection Content

Journal Article
|
Research

Trends in the availability and prices of quality-assured tuberculosis drugs: a systematic analysis of Global Drug Facility Product Catalogs from 2001 to 2024

Kohler S, Achar J, Mulder C, Sitali N, Paul N
2024-06-25 • Globalization and Health
2024-06-25 • Globalization and Health
BACKGROUND
The Global Drug Facility (GDF) of the Stop TB Partnership was launched in 2001 with the goal of increasing access to quality-assured tuberculosis (TB) drugs and products. ...
Journal Article
|
Research

Costs and import costs of past, present, and future TB drug regimens: a case study for Karakalpakstan, Uzbekistan

Kohler S, Sitali N, Achar J, Paul N
2022-11-23 • Journal of Public Health
2022-11-23 • Journal of Public Health
BACKGROUND
Tuberculosis (TB) drugs and their import are costly. We assessed how shorter TB drug regimens, which were non-inferior or superior in recent TB trials, can affect the cost...
Journal Article
|
Research

The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan

Kohler S, Sitali N, Achar J, Paul N
2022-08-03 • PLOS Global Public Health
2022-08-03 • PLOS Global Public Health

Tuberculosis (TB) programs depend on a continuous supply of large amounts of high-quality TB drugs. When TB programs procure TB drugs from international suppliers, such as the Global ...

Journal Article
|
Research

Programme costs of longer and shorter tuberculosis drug regimens and drug import: a modelling study for Karakalpakstan, Uzbekistan

Kohler S, Sitali N, Achar J, Paul N
2022-03-21 • ERJ open research
2022-03-21 • ERJ open research
BACKGROUND
The introduction of new and often shorter tuberculosis (TB) drug regimens affects the cost of TB programmes.

METHODS
We modelled drug purchase and import cost...
Journal Article
|
Research

A framework for assessing import costs of medical supplies and results for a tuberculosis program in Karakalpakstan, Uzbekistan

Kohler S, Sitali N, Paul N
2021-08-25 • Health Data Science
2021-08-25 • Health Data Science

BACKGROUND

Import of medical supplies is common, but limited knowledge about import costs and their structure introduces uncertainty to budget planning, cost ma...

Journal Article
|
Research

Health system support and health system strengthening: two key facilitators to the implementation of ambulatory tuberculosis treatment in Uzbekistan

Kohler S, Asadov DA, Bründer A, Healy S, Khamraev AK,  et al.
2016-07-12 • Health Economics Review
2016-07-12 • Health Economics Review

Uzbekistan inherited a hospital-based health system from the Soviet Union. We explore the health system-related challenges faced during the scale-up of ambulatory (outpatient) treatme...

Journal Article
|
Research

Ambulatory tuberculosis treatment in post-Semashko health care systems needs supportive financing mechanisms

Kohler S, Asadov D, Brunder A, Healy S, Khamraev AK,  et al.
2014-12-01 • International Journal of Tuberculosis and Lung Disease
2014-12-01 • International Journal of Tuberculosis and Lung Disease
The tuberculosis (TB) control strategy in the Republic of Karakalpakstan, Uzbekistan, is being changed to decentralised out-patient care for most TB patients by the Government of Uzbekis...

See more collections

World NTD Day
World NTD Day

Neglected tropical diseases (NTDs) impact nearly 1.7 billion people each year, causing serious illness or lifelong disability among many—often leading to stigma and exclusion—and killing an estimated 200,000. The vast majority of sufferers live in the world’s poorest countries.


The World Health Organization’s NTD roadmap 2021-2030 aims to address 20 tropical diseases through prevention, control, elimination, and/or eradication. But despite some progress, reaching all its targets will take better, far more accessible diagnostics and treatments along with more robust strategies, political commitment and resources.


To mark World NTD Day, this collection spotlights work by MSF and collaborators on improving approaches to snakebite envenoming, kala azar and noma. One study presents an innovative artificial intelligence-based snakebite diagnostic tool, while others evaluate shorter, less toxic drug regimens or different models of care. Several commentaries advocate for national/regional strategies adapted to contexts ranging from remote villages to active conflict zones. Another crucial factor is the climate crisis, which is intensifying the transmission and geographic spread of many NTDs.

MSF logo
MSF Scientific Days International 2023
No description available
Adapting essential care programs to Covid-19 pandemic times
Adapting essential care programs to Covid-19 pandemic times
As the ongoing Covid-19 pandemic grips the world, one of its most devastating indirect effects is the disruption to medical services for preventing and treating other life-threatening diseases—especially in countries with already-fragile health systems. For MSF and other global health actors this means not only responding to Covid-19 directly but also assessing its impact on other essential care and then adapting programs so they can keep serving patients despite the enormous obstacles. In this Collection you will find a selection of published articles and conference content from this year’s MSF Scientific Days 2021 conference content, encompassing a range of approaches, settings and medical challenges—from malaria, TB and HIV/AIDS prevention and care to digital health promotion and sexual and reproductive health.
View All Collections